NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-OD-22-049 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-055 from the NIH Guide for Grants and Contracts
Notice NOT-HS-22-010 from the NIH Guide for Grants and Contracts
Notice NOT-TR-22-018 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-001 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-23-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites R61/R33 applications that address health equity, drug costs, and access to new therapeutics or repurposed drugs for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Successful applications will seek to identify preferences for pharmacological treatment among racial and ethnic minority people living with AD/ADRD, assess whether cost barriers to pharmacological care exist for racial and ethnic minority people living with AD/ADRD, and quantify expenditures and health- related quality of life (HRQoL) among people interested in receiving novel or repurposed drugs for AD/ADRD.This FOA will support a study development phase (R61) to conduct rigorous stakeholder engagement with racial and ethnic minority groups to identify, measure, and assess the demand for new and repurposed drugs, and if successful, grantees will transition to an R33 phase for implementation of rigorous modeling of costs and health-related quality of life and dissemination of model findings.
Funding Opportunity RFA-OD-22-005 from the NIH Guide for Grants and Contracts. The goals of this RADx-UP Funding Opportunity Announcement (FOA) are to conduct social, ethical, and behavioral implications (SEBI) research to understand and reduce barriers to COVID-19 testing, as well as COVID-19 disparities that arise from barriers to testing among underserved and vulnerable populations. The funding for this initiative is provided from the American Rescue Plan Act of 2021, PL 117-2.
Funding Opportunity RFA-OD-22-006 from the NIH Guide for Grants and Contracts. The goals of this funding opportunity announcement (FOA) are to implement and rigorously evaluate SARS-CoV-2 rapid testing strategies in communities experiencing COVID-19 health disparities. These two-year Rapid Testing Research Projects will evaluate (1) rapid testing interventions to prevent and control COVID-19 transmission among underserved and vulnerable populations and (2) partnership-driven research to implement and evaluate rapid testing and reduce COVID-19 disparities. The funding for this program is provided from the American Rescue Plan Act of 2021, PL 117-2.
Funding Opportunity RFA-RM-22-008 from the NIH Guide for Grants and Contracts. The purpose of the FIRST Cohort is to transform culture at NIH-funded extramural institutions by building a self-reinforcing community of scientists committed to diversity and inclusive excellence (defined below). Implementing and sustaining cultures of inclusive excellence within the program has the potential to be transformational for biomedical research at the awardee institutions and beyond. This community will be built through recruitment of individuals who: are competitive for an advertised research tenure-track or equivalent faculty position (positions must be at the Assistant Professor (or equivalent) level), meet the criteria for NIH-defined Early Stage Investigators, and have demonstrated a strong commitment to promoting diversity and inclusive excellence.
Notice NOT-NS-22-080 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-077 from the NIH Guide for Grants and Contracts
Notice NOT-DA-21-079 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DE-23-004 from the NIH Guide for Grants and Contracts. This initiative is intended to accelerate research using animal models and precision medicine approaches to develop in utero treatments of congenital dental and craniofacial disorders. The long-term goal is to lay the groundwork for delivery of in utero treatments in human.
Funding Opportunity RFA-DE-23-005 from the NIH Guide for Grants and Contracts. This initiative is intended to accelerate research using animal models and precision medicine approaches to develop in utero treatments of congenital dental and craniofacial disorders. The long-term goal is to lay the groundwork for delivery of in utero treatments in human.
Notice NOT-DA-22-053 from the NIH Guide for Grants and Contracts
Notice NOT-AT-22-012 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-052 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-032 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-22-019 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRC). The overarching goal of this initiative is to establish a network of Centers that will work collaboratively to define the cause(s) of and discover improved treatments for ME/CFS. A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as local resources and national leaders in ME/CFS research. Successful CRC research programs will facilitate research in ME/CFS through conducting of 1) collaborative basic and/or clinical research on ME/CFS; 2) longitudinal studies of individuals with ME/CFS within each ME/CFS CRC and across CRCs within the network; 3) access to information related to ME/CFS for basic and clinical researchers, academic and practicing physicians, healthcare professionals, patients, and the lay public. Clinical data and biospecimen sharing are required, and data management for efficient data collection and data sharing, as well as biospecimen sharing will be addressed through the separate data management and coordinating center (DMCC). Institutions must be committed to the establishment and continuation of the proposed ME/CFS CRC. Funding decisions will focus on those applications most likely to make highly impactful contributions to ME/CFS research, as well as on those with the greatest potential to collaborate effectively across the ME/CFS CRC program.
Funding Opportunity RFA-NS-22-020 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite new cooperative agreement applications for the Data Management and Coordinating Center (DMCC), which supports the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRC). This FOA will support the DMCC (U24) cooperative agreement that will focus on providing the infrastructure and support to the individual ME/CFS CRCs in their activities. Data management for efficient data collection as well as data mining and data sharing will be addressed in the data management and coordinating center (DMCC), as well as coordination of tools to identify and access available ME/CFS biospecimens. The ME/CFS CRCs will establish a network to facilitate research through: 1) collaborative basic and/or clinical research on ME/CFS; 2) provide and maintain tools for data and biospecimen sharing; 3) access to information related to ME/CFS for basic and clinical researchers, academic and practicing physicians, healthcare professionals, patients, and the lay public; and 4) facilitation of community outreach and engagement in the research activities.